Citation
Annual Report 2023
TL;DR
Global R&D network with autonomous regional centers
Documents Novo Nordisk's $26 billion diabetes care revenue and global R&D organization with research centers in Denmark, United States (Boston, San Francisco Bay Area), China, and India. Provides evidence for the company's calibrated geographic gene flow model with scientist rotation programs.
Demonstrates how a major pharmaceutical company structures gene flow to transfer knowledge while preserving local adaptation.
Key Findings from A/S (2023)
- Global R&D network with autonomous regional centers
- Scientist rotation programs enable knowledge transfer
- Each site maintains local practices suited to regional talent markets
- Insulin analogs combine Copenhagen manufacturing with California protein engineering